The outcome of IHE initiatives is providing better information for developing health policy and best medical practices. IHE disseminates information in many ways. In addition to publications in peer-reviewed journals, IHE produces books and a variety of reports synthesizing information in a particular field.
If you cannot find the publication or report you are seeking, please contact us at [email protected]. Thank you!
Refine your search by clicking filters to the left.
The Institute for Health Economics (IHE) is conducting an invitational, virtual policy roundtable on progressive fibrosing interstitial lung disease (PF-ILD) on November 20th, 2020. This policy roundtable will seek to gain multi-stakeholder consensus on policy recommendations intended to optimize care for PF-ILD patients Key areas for discuss are in the following three areas: Multi-disciplinary…
The IHE Life Sciences Commercialization Program supports Alberta, Saskatchewan, Manitoba and British Columbia-based life sciences companies with promising, market-ready healthcare technology that are currently seeking procurement in Canadian or international markets. Support includes the development of an economic model to quantify the technology value…
News items are kept on the IHE website for 6 months. If you require an older news item, please contact us at [email protected].
For media inquiries, please contact John Sproule, Senior Policy Director at [email protected]
The IHE has a dedicated Life Sciences SME Platform within the Institute that collaborates with and provides support for SMEs in the life sciences. The IHE provides services to: educate SMEs and support organizations (e.g., accelerators) on the value and use of health economics to support decisions along the commercialization journey as well as procurement efforts; provide early-stage…
| Sean M. Bagshaw, Dat Tran, Dawn Opgenorth, Xiaoming Wang, Danny Zuege, Armann Ingolfsson, Henry T. Stelfox, Thanh Nguyen
Delay in transfer from intensive care unit (ICU) may contribute to strained capacity. Using a population-based patient cohort in 17 ICUs in Alberta between 2012 and 2016, this paper describes the epidemiologic features and healthcare costs attributable to potentially avoidable delays in ICU discharge. Potentially avoidable discharge delay occurred in approximately 70% of ICU patients…
Summary: We examined the association between optimal control of dyslipidemia and mortality and healthcare costs in patients with high risk for cardiovascular disease (HRCVD) between 2012-2016 in Alberta, Canada. HRCVD patients who were optimally controlled had lower mortality and incurred modestly higher costs, compared to those who were not. Secondary prevention patients with…